CML patients in England win access to Incyte’s Iclusig
admin 2nd May 2017 Uncategorised 0Chronic Myeloid Leukaemia (CML) patients in England who are resistant or intolerant to second generation tyrosine kinase inhibitor (TKI) therapies are on the brink of getting full-access to Incyte’s Iclusig on the NHS following a nod from NICE.
More: CML patients in England win access to Incyte’s Iclusig
Source: News